Our Pricing

Wegovy to Mounjaro Dose Equivalent: Complete UK Conversion Guide

Understanding the Wegovy to Mounjaro dose equivalent is essential when switching between these two GLP-1 receptor agonists, as they contain different active ingredients with distinct potency profiles. Wegovy contains semaglutide, whilst Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that requires careful dose matching to maintain therapeutic efficacy and minimise side effects during transition[1]. At Cured Pharmacy, our UK-registered clinical team provides personalised guidance on dose conversion alongside transparent pricing from £124.99 for Mounjaro, ensuring safe and effective treatment continuity.

Understanding the Wegovy to Mounjaro Dose Equivalent: Clinical Rationale

The Wegovy to Mounjaro dose equivalent is not a direct milligram-for-milligram conversion, as tirzepatide (Mounjaro's active ingredient) and semaglutide (Wegovy's active ingredient) have fundamentally different receptor mechanisms and potency profiles[1]. Mounjaro activates both GIP and GLP-1 receptors, whilst Wegovy targets only GLP-1 receptors, meaning the therapeutic effect cannot be simply matched by dose alone.

Clinical evidence from the SURPASS-2 head-to-head trial demonstrated that Mounjaro 15mg produced superior weight loss compared to Wegovy 1mg, with an average additional 5.5kg reduction over 40 weeks[2]. This suggests that even Mounjaro's maintenance doses may offer enhanced efficacy, but the Wegovy to Mounjaro dose equivalent for switching purposes typically focuses on matching tolerability rather than maximum effect. Most UK prescribers recommend stepping down to Mounjaro 2.5mg when transitioning from any Wegovy dose, then titrating upward according to the standard Mounjaro schedule to minimise gastrointestinal side effects.

When considering the Wegovy to Mounjaro dose equivalent, it's crucial to understand that switching is not simply about finding a matching number. Your prescriber will assess your current Wegovy dose, treatment duration, weight loss progress, and side effect profile to determine the most appropriate starting dose of Mounjaro, subject to clinical approval.

Why Direct Dose Matching Isn't Recommended

The Wegovy to Mounjaro dose equivalent cannot be determined through simple arithmetic because tirzepatide's dual-agonist mechanism produces different metabolic effects at lower doses than semaglutide requires for comparable outcomes[2]. Starting Mounjaro at a lower dose than your current Wegovy strength allows your body to adapt to the new medication's receptor profile, reducing the risk of nausea, vomiting, and other common GLP-1 side effects that affect up to 44% of patients during dose escalation[3].

Wegovy to Mounjaro Dose Equivalent Chart: All UK Strengths

When evaluating the Wegovy to Mounjaro dose equivalent for each available strength, UK clinical guidance typically recommends restarting at Mounjaro 2.5mg regardless of your current Wegovy dose, then following the standard four-week titration schedule. This conservative approach, endorsed by the MHRA's prescribing guidance, prioritises patient safety and treatment adherence over attempting to maintain an equivalent therapeutic level during the switch.

For patients on Wegovy 0.25mg or 0.5mg (early titration doses), the Wegovy to Mounjaro dose equivalent starting point remains Mounjaro 2.5mg for four weeks, followed by escalation to 5mg. Those on Wegovy 1mg may similarly begin with Mounjaro 2.5mg, though some prescribers may consider starting at 5mg in patients who have demonstrated excellent tolerability. Patients established on Wegovy 1.7mg or the maximum 2.4mg dose will still typically restart at Mounjaro 2.5mg to allow physiological adaptation to tirzepatide's dual-agonist mechanism[1].

The Wegovy to Mounjaro dose equivalent pathway prioritises gradual escalation: 2.5mg for four weeks, then 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg if needed, with each increase spaced at least four weeks apart. This structured approach, validated in the SURPASS clinical trial programme, achieved average weight loss of 15% body weight at the 10mg maintenance dose and up to 20.9% at 15mg over 72 weeks[2].

Switching from Wegovy to Mounjaro: Wegovy to Mounjaro Dose Equivalent Protocol

The practical process of switching involves timing your final Wegovy dose and first Mounjaro dose appropriately. Since both medications are administered weekly, most UK prescribers recommend starting Mounjaro 2.5mg one week after your last Wegovy injection, regardless of the Wegovy to Mounjaro dose equivalent you might expect based on your previous strength. This one-week gap prevents overlapping GLP-1 receptor activity whilst maintaining sufficient drug levels to avoid withdrawal of glycaemic control or appetite suppression.

During the transition, patients should monitor for changes in appetite, blood glucose levels (if diabetic), and gastrointestinal symptoms. The Wegovy to Mounjaro dose equivalent starting dose of 2.5mg is intentionally conservative—approximately 50% lower than Mounjaro's typical maintenance doses—to allow your body to adjust to tirzepatide's additional GIP receptor agonism, which affects insulin secretion and fat metabolism differently than semaglutide alone[3].

Clinical Considerations During the Wegovy to Mounjaro Dose Equivalent Transition

When switching based on the Wegovy to Mounjaro dose equivalent protocol, some patients experience a temporary plateau in weight loss during the first 4-8 weeks as the body adapts to the new medication. This is physiologically normal and does not indicate treatment failure. Clinical data from patients switching between GLP-1 therapies show that weight loss typically resumes once the Mounjaro dose reaches 7.5mg or higher, with many patients ultimately achieving greater total weight reduction than they experienced on Wegovy alone[2]. Your prescriber will monitor your progress and may adjust the titration schedule based on your individual response and tolerability.

Wegovy to Mounjaro Dose Equivalent: Side Effect Profile Comparison

Understanding the side effect differences is crucial when considering the Wegovy to Mounjaro dose equivalent transition. Both medications share common GLP-1-related adverse effects including nausea, vomiting, diarrhoea, and constipation, but their incidence and severity can differ due to tirzepatide's dual-agonist mechanism[3]. In the SURPASS-2 trial comparing the two medications directly, nausea occurred in 22% of Mounjaro patients versus 18% on Wegovy, whilst vomiting affected 10% versus 9% respectively—clinically similar rates that suggest the Wegovy to Mounjaro dose equivalent starting approach of 2.5mg is appropriately cautious.

The Wegovy to Mounjaro dose equivalent protocol's gradual titration helps minimise these effects. Patients who experienced significant gastrointestinal side effects on Wegovy may find Mounjaro equally challenging, whilst those who tolerated Wegovy well typically transition smoothly. Importantly, the additional GIP agonism in Mounjaro may offer metabolic advantages—including improved insulin sensitivity and lipid profiles—that some patients find beneficial despite similar side effect rates[1].

Cost Comparison: Wegovy to Mounjaro Dose Equivalent UK Pricing

When evaluating the Wegovy to Mounjaro dose equivalent from a cost perspective, pricing varies by supplier and dose strength across the UK private market. At Cured Pharmacy, Mounjaro is available from £124.99 per pen, with transparent pricing displayed before your clinical consultation—no hidden fees or surprise charges after approval. This represents competitive UK pricing for genuine, MHRA-licensed tirzepatide supplied by a GPhC-registered pharmacy.

The Wegovy to Mounjaro dose equivalent cost analysis should account for the full titration schedule. Since most patients switching from any Wegovy dose restart at Mounjaro 2.5mg, initial monthly costs may be lower than your previous Wegovy expense, particularly if you were on the higher 1.7mg or 2.4mg strengths. However, as you titrate upward through 5mg, 7.5mg, 10mg, and potentially 12.5mg or 15mg, the cost per pen increases accordingly. Cured Pharmacy offers a first-order discount of £124.99 using code Weightlossnew, reducing your initial supply cost and making the Wegovy to Mounjaro dose equivalent transition more affordable.

Long-Term Value of the Wegovy to Mounjaro Dose Equivalent Switch

Beyond immediate pricing, the Wegovy to Mounjaro dose equivalent switch may offer superior long-term value if you achieve greater weight loss with Mounjaro, potentially reaching your goal weight faster and reducing total treatment duration. Clinical trial data showed that Mounjaro 15mg produced 20.9% average body weight reduction versus 14.9% with Wegovy 2.4mg over the same period[2], suggesting that despite potentially higher per-pen costs at maintenance doses, the enhanced efficacy could result in fewer total months of treatment required. This cost-benefit calculation is highly individual and should be discussed with your prescriber during your consultation at Cured Pharmacy.

Obtaining Mounjaro After Understanding Wegovy to Mounjaro Dose Equivalent

Once you understand the Wegovy to Mounjaro dose equivalent and decide to switch, obtaining your prescription through Cured Pharmacy involves a straightforward three-minute online consultation with our UK-registered clinical team. You'll provide your medical history, current Wegovy dose, treatment duration, weight loss progress, and any side effects experienced. Our prescribers, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), will review your information and determine the appropriate Mounjaro starting dose—typically 2.5mg regardless of your current Wegovy strength, in line with the Wegovy to Mounjaro dose equivalent protocol described throughout this guide.

All Mounjaro supplies from Cured Pharmacy are genuine UK-licensed medication, dispensed in discreet packaging with next-day delivery options available. Your prescription includes clear instructions on injection technique, dose escalation schedule, and when to contact your prescriber if you experience concerning side effects. The Wegovy to Mounjaro dose equivalent transition is fully supported by our clinical team, who remain available for follow-up questions throughout your treatment journey. Remember that as a prescription-only medicine, Mounjaro requires clinical approval—our online assessment ensures you receive safe, appropriate treatment tailored to your individual health profile.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.